Meeting
2015 Genitourinary Cancers Symposium
Prognostic factor for overall survival in the "difficult-to-treat" germ cell tumor patients.
Authors
Terukazu Nakamura
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
Terukazu Nakamura , Masakatsu Oishi , Takashi Ueda , Takumi Shiraishi , Hiroyuki Nakanishi , Yoshio Naya , Fumiya Hongo , Koji Okihara , Tsuneharu Miki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 402)
DOI
10.1200/jco.2015.33.7_suppl.402
Abstract #
402
Poster Bd #
J12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prognostic significance of raised serum tumor markers (STM) after 2 cycles of chemotherapy in men with intermediate- and poor-risk non-seminomatous testicular germ cell tumors (NSGCT) treated at a single-centre in India.
First Author: ANKUR NANDAN VARSHNEY
Poster
2021 ASCO Annual Meeting
Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.
First Author: Adam Uprichard
Poster
2015 Genitourinary Cancers Symposium
Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy.
First Author: Orvar Gunnarsson
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto